Tesamorelin
$69.99
In stockTesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). It stimulates the pituitary gland to release growth hormone and increases circulating insulin-like growth factor 1 (IGF-1). FDA-approved tesamorelin medications are administered subcutaneously to reduce excess abdominal fat in adults with HIV-associated lipodystrophy.
| SKU | RC-ST-TESA-10MG |
|---|---|
| Manufacturer | Strandix Peptides |
| Form | Lyophilized Powder |
| Strength | 10 mg |
| Size | 3 mL Vial |
| Reported Result | >99% |
| Stock | In stock |
| Documentation Status | Pending Final COA |
Product Description
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). It stimulates the pituitary gland to release growth hormone and increases circulating insulin-like growth factor 1 (IGF-1). FDA-approved tesamorelin medications are administered subcutaneously to reduce excess abdominal fat in adults with HIV-associated lipodystrophy.
Research has focused particularly on visceral adipose tissue, the fat surrounding internal abdominal organs. This differs from subcutaneous fat located directly beneath the skin.
What research has shown:
Reduced visceral fat: A randomized trial involving 412 adults with HIV-associated abdominal fat accumulation found that visceral fat decreased by 15.2% with tesamorelin, compared with a 5.0% increase with placebo, over 26 weeks.
Improvements in certain lipid markers: The same trial reported reductions in triglycerides and improvements in the total-cholesterol-to-HDL ratio. These marker changes do not establish a reduction in cardiovascular events.
Changes in abdominal appearance: Phase III research reported improvements in participants’ distress about belly appearance. Abdominal subcutaneous fat did not significantly change, illustrating the distinction between reducing visceral fat and general fat loss.
Preliminary liver-fat findings: A separate randomized study in adults with HIV and abdominal fat accumulation found modest reductions in liver fat.
Storage and handling: Store lyophilized peptide according to manufacturer documentation, protected from light and moisture. Confirm sequence, modification, assay, purity, sterility status, and formulation. Do not copy storage instructions from branded tesamorelin products unless the formulation is identical and authorized.
Third-party testing status.
| Batch / Lot | Reported Result | Tested | Partner | Status | Document |
|---|
.png)